Rosalind Franklin University Helix 51 Company Saros Therapeutics Receives Second $2 Million Award to Advance Cancer Immunotherapy

Positive

AI Analysis

Summary

Saros Therapeutics, part of Rosalind Franklin University's Helix 51 incubator, received its second National Cancer Institute Phase II award of approximately $2 million to advance cancer immunotherapy development.

Outcome Details

Second Phase II NCI award of approximately $2 million

Importance:4/10

Sentiment:

0.70

cancer_immunotherapyNCI_fundingPhase_2incubator_companygrant

Related Companies

$NHPAP

Read the original article

Published by PR Newswire Biotech on October 2, 2026 4:00 PM

Read Original